Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Supplemental Figure S2: XTX301 demonstrates enhanced activity upon proteolytic cleavage in primary cells. (a) Primary mouse splenocytes were pre-activated with PMA & Ionomycin and then incubated with varying doses of rm IL-12 and murine surrogate test articles for 24 hours, and supernatants were assessed by IFN- ELISA. (b) Human peripheral blood mononuclear cells (PBMCs) were preactivated with PMA + Ionomycin and incubated with test articles for 4 days and (c) Cynomolgus monkey PBMCs were preactivated with PMA + Ionomycin and incubated with varying doses of rhIL-12 and test articles for 24 hours and evaluated for IFN- production by ELISA.